NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag. 
 
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
 
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.